Skip to main content

Table 1 Clinicopathological parameters compared to ADAM33 promoter methylation analyzed by Chi-square Test or Fisher's Exact Test.

From: ADAM33 gene silencing by promoter hypermethylation as a molecular marker in breast invasive lobular carcinoma

Variate n a (%) ADAM33Methylation (%) p-value
   Positive Negative  
Tumor Stage     
0/I 14 (20.0) 4 (28.6) 10 (71.4) 0.641
II 33 (47.1) 14 (42.4) 19 (57.6)  
III/IV 23 (32.9) 8 (34.8) 15 (65.2)  
Tumor Size b     
pT1/pTis 20 (27.4) 6 (30.0) 14 (70.0) 0.174
pT2 38 (52.1) 14 (36.8) 24 (63.2)  
pT3/pT4 15 (20.5) 9 (60.0) 6 (40.0)  
Histological Grade (SBR)     
I 19 (27.1) 8 (42.1) 11 (57.9) 0.799
II 33 (47.1) 14 (42.4) 19 (57.6)  
III 18 (25.7) 6 (33.3) 12 (66.7)  
Lymph Node Status     
Negative 34 (47.9) 13 (38.2) 21 (61.8) 0.965
Positive 37 (52.1) 15 (40.5) 22 (59.5)  
Estrogen Receptor Status (ER)     
Negative 12 (17.1) 4 (33.3) 8 (66.7) 0.751
Positive 58 (82.9) 24 (41.4) 34 (58.6)  
ERBB2 Status     
Negative 43 (66.2) 18 (41.9) 25 (58.1) 0.378
Positive 22 (33.8) 6 (27.3) 16 (72.7)  
Progesterone Receptor Status (PR)     
Negative 15 (24.6) 4 (26.7) 11 (73.3) 0.678
Positive 46 (75.4) 17 (36.9) 29 (63.1)  
Metastasis Status     
Negative 55 (79.7) 23 (41.8) 32 (58.2) 0.548
Positive 14 (20.3) 4 (28.6) 10 (71.4)  
Recurrence Status     
Negative 63 (91.3) 23 (36.5) 40 (63.5) 0.201
Positive 6 (8.7) 4 (66.7) 2 (33.3)  
Histological Tumor Type     
Invasive Ductal Carcinoma 51 (70.8) 13 (25.5) 38 (74.5) 0.0002
Invasive Lobular Carcinoma 21 (29.2) 16 (76.2) 5 (23.8)  
  1. aOnly female patients with primary invasive breast cancer were included. bAccording to TNM classification [10].